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Abstract   
Background: The association between international-normalized-ratio (INR) correction and 
mortality in patients with major bleeding on vitamin-K-antagonists (VKA) is important for 
evaluating the efficacy of reversal agents for oral anticoagulants.  
Objectives: We evaluate if INR correction (defined as ≤1.3) following intervention in major 
bleeding on VKA is associated with better survival, and if there is a dose-response relationship 
between Vitamin K (VK) and INR correction.  
Methods: Data on patients’ characteristics, haematological management and 30-day outcomes 
reported by 32 UK hospitals (October 2013 - August 2016) were analysed. Associations 
between INR correction and: (a) 30-day mortality; (b) VK dose were estimated using 
multivariable logistic regression, using multiple imputation to handle missing INR values.  
Results: Of 1,771 patients, 77%, 73% and 33% received prothrombin-complex-concentrate 
(PCC), VK (92% intravenous) and red cells and fresh frozen plasma transfusion respectively. 
Proportionally more intracranial haemorrhage (ICH) cases (87%) than non-ICH cases (69%) 
received PCC. VK administration did not vary by ICH group, with 10mg (33%) and 5mg (28%) 
doses being the most common. Higher doses of VK (10mg) were more likely to correct INR 
than lower doses (5mg). Post-intervention INR>1.3 in treated patients was associated with 3.2 
(95%CI: 2.1–4.9) times higher odds of death within 30 days, compared with INR≤1.3, with no 
difference between ICH and non-ICH.  
Conclusions: INR correction after intervention to manage major bleeding on VKA is associated 
with better survival. Higher VK doses (10mg) improve INR correction more than lower doses 
(5mg) in major bleeding, but further studies are warranted to compare the relative benefits/risks 
of 5mg versus 10mg doses. 
  





Vitamin K antagonists (VKA) such as warfarin have been the mainstay of oral anticoagulation 
therapy (OAC) for many decades worldwide. Like all anticoagulant agents, VKA are 
associated with development of major bleeding and intracranial haemorrhage (ICH), whose 
annual incidence from recent studies has varied from 1.6% - 3% and <1%, respectively [1].  
 
The UK guideline for the management of major bleeding associated with VKA recommends 
that prothrombin complex concentrate (PCC) and intravenous vitamin K (5mg) should be used 
to treat the bleeding, and that fresh frozen plasma (FFP) transfusion should only be given if 
PCC is not available [2]. However, only a few small randomised controlled trials have 
compared the efficacy and safety of FFP versus PCC in patients with major bleeding associated 
with warfarin [3, 4] and there have been no clinical trials to determine the most appropriate 
dose of vitamin K for treatment of major bleeding, in terms of its capacity to sustain the reversal 
action of PCC/FFP whilst avoiding potential difficulties with achieving therapeutic INR levels 
when anticoagulation is resumed [5].  
 
Further, most trials that have compared PCC with FFP have used as a primary outcome 
laboratory markers such as the correction of the international normalised ratio (INR), rather 
than a clinical outcome measure [4, 6]. The main reason for this is the large sample sizes needed 
to perform such trials, which in turn will require a long period of time and incur significant 
costs delivering these trials in a challenging and unpredictable environment. Only a few small 
studies have evaluated the associations between INR correction and mortality in patients who 
have developed major bleeding on warfarin [7, 8]. Evaluating the relationship between 
correction of laboratory markers and clinical outcomes (particularly mortality) for management 
of major bleeding associated with OAC is important not only for warfarin, but also possesses 
relevance with the advent of new antidotes for direct oral anticoagulants (DOACs).  
 
In this paper we describe the haematological management of major bleeding cases associated 
with VKA in the UK and in particular we evaluate: (a) if INR correction (defined as ≤1.3) 
following intervention is associated with lower in-hospital mortality up to 30 days; and (b) if 






The ORANGE study (October 2013 to August 2016) was a prospective cohort study that 
collected data from 32 UK hospitals on the presentation and clinical outcomes of patients who 
were admitted for a major bleeding episode whilst on OAC therapy such as VKA or direct 
OACs, enabling the identification of key risk factors for mortality following OAC-associated 
major bleeding [9]. For this paper, data on a subgroup of patients reported to the ORANGE 
study who were on a VKA (predominantly warfarin) were extracted for analysis. Major 
bleeding was defined in accordance with the criteria set by the International Society on 
Thrombosis and Haemostasis[10]; additionally patients receiving transfusion of FFP, PCC or 
other haemostatic agents were also included. Details of study approvals, case definition, 
identification and validation have been described previously [9]. Data comprised information 
on patient demographics, co-morbidities, bleeding sites, haematological laboratory results, 
management of bleeding and first outcome up to 30 days (death, discharge or continued 
hospitalisation). Patients were not approached by the research teams and their management was 
not altered for the purpose of this study.  
 
Bleeding sites were categorised into intracranial (intracerebral, subarachnoid and subdural 
bleeding), upper and lower gastrointestinal and “Other” (visceral, genitourinary, musculo-
mucosal-skeletal and elsewhere not already mentioned); patients with multiple sites of bleeding 
would be assigned to a single category according to the above-stated order. Two sets of 
patients’ laboratory results were collected: (T1) within 1 day of reported date of bleeding and 
prior to any treatment by haemostatic agents (such as PCC) or red cells and FFP transfusion; 
and (T2) the first result following administration of any treatment (PCC or vitamin K or FFP), 
provided it was within 2 days of reported date of bleeding. If more than one product was given, 
this would be the earliest result after the first product. If no intervention was given, the earliest 
available result following T1 INR and within 2 days of reported date of bleeding was used. The 
reason for setting an upper limit for inclusion of results is to evaluate the predictive value of 
INR that is measured proximally to onset of bleeding and time of intervention; even without 
intervention INR will tend to decrease over time once anticoagulation has been stopped. Test 
results for haemoglobin, platelet count, prothrombin time (PT), INR, activated partial 
thromboplastin time (APTT), serum creatinine and alanine aminotransferase (ALT) were 
extracted for this analysis. Information on red cells and FFP transfusion and reversal agents 
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administered within 2 days for management of bleeding were recorded. These included 
Vitamin K, PCC and FFP, as well as less commonly used haemostatic agents (recombinant 
activated factor VII, factor eight inhibitor bypassing activity, fibrinogen concentrate).  
 
Statistical Analysis  
Variables were summarised as frequencies/proportions, means/standard deviations or 
median/interquartile ranges, as appropriate. The association of T2 INR with primary outcome 
(in-hospital death within 30 days of admission for major bleeding) was investigated using 
multivariable logistic regression, adjusting for bleed site (grouped as ICH or non-ICH) and age. 
The time elapsed (in hours) between treatment and T2 INR was included as a potential 
confounder, on the basis that critically ill patients were more likely to be promptly monitored 
and thus return elevated INR readings. Patients who received no treatment within the 2-day 
window, or whose T2 INR preceded treatment, were considered untreated and the time between 
T1 and T2 INR results was used as proxy. Tests of interaction were used to examine whether 
the effect of INR on death would differ between: (a) treated and untreated patients; and (b) ICH 
and non-ICH patients. Random effects models were fitted to investigate potential hospital 
clustering effects. All tests were two-sided at 5% level of significance. 
 
Due to missing values in the primary outcome (death) and main exposure (T2 INR), multiple 
imputation (MI) was used to create and analyse 60 multiply imputed datasets under the 
assumption that data were missing at random. Incomplete variables were imputed under fully 
conditional specification, using logistic regression for binary variables and predictive mean 
matching with 5 nearest neighbours for continuous variables, separately by treatment status to 
allow for investigation of interaction; variables were log- or power-transformed to an 
approximate normal distribution where required prior to imputation. Laboratory results that 
correlated (r≥0.15) with INR values (comprising PT, APTT, haemoglobin, platelet count, 
serum creatinine and ALT), as well as factors known to affect T2 INR (history of liver and 
renal disease, administration of PCC, FFP and vitamin K) were selected as auxiliary variables 
in the imputation model to improve prediction of missing values. The probability of INR being 
missing was postulated to be associated with a short hospital stay (whether due to discharge, 
transfer or death), absence of intervention/treatment and variation in INR monitoring practices 
across hospitals; for this, hospitals were grouped by proportion of their patients missing T1 
INR results at admission (0%, 1-4%, 5-9% and ≥10%). Mann-Whitney and Chi-squared tests 
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were used to confirm the hypothesised associations. Finally the parameters of substantive 
interest were estimated in each imputed dataset separately and combined using Rubin’s rules 
[11]. For comparison, the analysis was performed on the subset of complete cases.  
 
For the secondary analysis, logistic regression was used to investigate the association between 
Vitamin K dose and T2 INR correction, adjusting for PCC dosing, ICH, T1 INR and T1 serum 
creatinine. Continuous variables were modelled using linear and quadratic functional forms as 
appropriate. Analysis was performed on both complete cases and the multiply imputed datasets 
and checked for agreement. The predicted probabilities of T2 INR correction were plotted for 
different Vitamin K doses, holding other covariates at fixed values, for non-ICH and ICH 
patients. All analyses were performed using STATA version 14 (StataCorp LP, USA). 
 
Results 
Over the study period 1,771 patients on VKA (1,763 Warfarin, 7 Sinthrome, 1 Phenindione) 
presented with major bleeding; patient characteristics and their co-morbidities have been 
detailed in a previous publication [9]. In summary, the median age (interquartile range) of 
patients was 79 (71–85) years and the main indications for VKA were atrial fibrillation (71%), 
venous thromboembolism (20%) and mechanical heart valve (12%), with 11% of patients 
having more than one indication. The distribution of bleeding sites is given in Figure 1; 
intracranial haemorrhage and gastrointestinal bleeding accounted for 46% and 30% of cases 
respectively.   
 
Table 1 shows the haematological management of cases. Overall, 77% received PCC and this 
was proportionally higher in ICH cases (87%) than non-ICH cases (69%). Vitamin K was 
administered to 1,296 (73%) patients predominantly through the intravenous (IV) route (92% 
IV, 4% oral, <1% IV and oral, 4% not recorded). The most common doses prescribed were 
10mg (33%) and 5mg (28%) with no difference between ICH and non-ICH cases; however, 
there were proportionally fewer patients receiving 10mg or more amongst those with a 
mechanical heart valve compared to those without (24% vs. 34%). Overall 33% of patients 
received red blood cells (RBC) and/or fresh frozen plasma (FFP); both RBC and FFP 
transfusion were more likely for non-ICH cases (57% and 6% respectively) than ICH cases 




Out of 1771 patients, 358 (20%) died in hospital within 30-days of admission for major 
bleeding, with 52 (3%) lost to follow-up. A valid T2 INR result was available for 1222 (69%) 
patients; for a subgroup of 955 patients for whom exact timings were available, the median 
(interquartile range) time elapsed between treatment (or T1 INR if not treated) and T2 INR 
measurement was 9.0 (3.6-19.9) hours and 9.9 (5.5-18.4) hours for the treated and untreated 
groups respectively. T2 INR remained uncorrected (>1.3) in 20% and 40% of ICH and non-
ICH patients respectively (Figure 2). Analysis of complete cases (n=1191) showed that the 
effect of T2 INR>1.3 on 30-day mortality depended on treatment status; no significant 
association was seen in the untreated group whereas it was associated with 3.2 (95%CI: 1.9-
5.2) times greater odds of death in the treated group, after adjusting for ICH and age. 
Additionally adjusting for time of measurement increased the corresponding odds in the treated 
group to 4.2 (95%CI: 2.1-8.3) times, but this was based on a smaller sample with available data 
(n=853). Analysis using 60 multiply-imputed datasets (n=1771) showed the odds of death were 
3.2 (95%CI: 2.1-4.9) times higher in those with INR>1.3 compared to INR≤1.3 at T2 in the 
treated group, with borderline evidence of a lesser association in the untreated group. There 
was no evidence that the association between INR and mortality differed between those with 
ICH vs. non-ICH, and no evidence of hospital-level variation. The unadjusted and adjusted 
odds ratios in both analyses are presented in Table 2; further details of the imputation model 
are provided in Appendix 1 (supplementary table).  
 
For the secondary analysis, a logistic regression model with T2 INR correction as the outcome 
was fitted with Vitamin K dose (linear and quadratic), PCC dose, ICH, T1 INR and T1 serum 
creatinine as covariates; additionally adjusting for a patient’s weight and FFP administration 
did not change the estimated effect of Vitamin K and there was no evidence that its effect 
differed between ICH and non-ICH patients. Due to a relatively high number of missing T2 
INR results (31%), only complete case (n=1046) results are reported; analysis of the multiply 
imputed datasets did not show materially different results. The predicted probabilities of T2 
INR correction are illustrated in Figure 3 for a patient with pre-treatment INR of 3 and serum 
creatinine of 100 µmol/L. There is a discernible dose-response relationship, with the 
incremental effect being greatest in patients receiving no or lower doses of PCC, for both ICH 
and non-ICH cases; however, over the range of lower doses there is greater uncertainty as 






Key results  
In this study we report on the haematological management and outcomes of 1,771 patients on 
VKA who were hospitalised for major bleeding in the UK and the association between INR 
correction and mortality. The overall mortality rate was 20% with the key results being:  
- PCC, Vitamin K and FFP transfusion were administered to 77%, 73% and 4% of cases 
respectively. PCC administration was higher for ICH cases than non-ICH cases, while 
FFP was relatively more common for non-ICH cases.  
- The adjusted odds of death were 3.2 (95%CI: 2.1-4.9) times higher in those whose INR 
was not corrected to ≤1.3 after receiving treatment; this association was the same for 
ICH and non-ICH cases.  
- Vitamin K was administered most commonly in 10mg and 5mg doses (33% and 28% 
of all patients respectively), with no significant difference between ICH and non-ICH 
patients. Higher doses of Vitamin K were more likely to correct INR than lower doses. 
 
Interpretation of results  
This UK multicentre study is hitherto the largest to report on the haematological management 
of major bleeding associated with VKA and the association between INR correction and 
mortality, using prospectively collected hospital data as opposed to data linkage to healthcare 
databases. The use of PCC in this study was higher than other international studies [12, 13], 
because the UK guidelines recommend that PCC be used as a first line treatment in these cases, 
and FFP should only be given if PCC is not available [14]. It is noteworthy that PCC was more 
likely to be given to ICH patients whilst non-ICH patients were more likely to receive red cells 
and FFP transfusion. A possible explanation is that non-ICH bleeding would more likely 
involve significant blood loss and thus necessitate more red cells and FFP transfusion for 
volume replacement compared with ICH; however, there is a further question of whether non-
ICH bleeds should also be treated with PCC, independently of whether blood components were 
administered, that current guidelines have yet to specifically address.  
 
We identified that administration of Vitamin K was tri-modal, with none, 5mg and 10mg being 
the most common. This spread is not surprising given the lack of clinical trials investigating 
appropriate dosages for VKA associated major bleeding. This is also a reflection of differences 
in national guidelines, with some recommending 5mg (UK included) [14] and others 
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recommending as much as 10mg (Australia, USA) [15, 16]. Additionally, we noted that higher 
doses (≥10mg) of Vitamin K were less commonly given to heart valve patients, suggesting that 
there may be anxiety amongst clinicians that higher doses could complicate attainment of 
therapeutic INR in a group for whom restarting of anticoagulation is of greater priority [5]. Our 
analysis showed an approximately linear dose-dependence of Vitamin K on the probability of 
achieving INR correction, indicating therefore that 10mg would be beneficial for patients. The 
benefit-risk balance of prescribing 5mg versus 10mg of Vitamin K in major bleeding would 
nonetheless need to be confirmed by further interventional studies. 
 
There are no official guidelines on the timing and frequency of INR monitoring in the 
management of major bleeding. We found that uncorrected INR (>1.3), measured after receipt 
of treatment, is an important risk factor for mortality in VKA associated major bleeding; this 
association is particularly strong in patients who have received some form of intervention and 
holds true for both ICH and non-ICH cases. In the case of ICH, one study of 853 patients 
demonstrated that a combination of INR reversal <1.3 within 4 hours and systolic blood 
pressure (BP) of <160 mmHg at 4 hours were associated with lower rates of hematoma 
enlargement (OR=0.28; 95%CI: 0.19-0.42; p<0.001) and in-hospital mortality (OR=0.60; 
95%CI: 0.37-0.95; p=0.03) [17]; these are broadly consistent with our findings on the strength 
of association between INR and mortality, taking into account small differences in the 
subgroup specification and INR timings. Another smaller study using the electronic health 
records of 405 patients receiving FFP for major bleeding showed that failure to correct INR to 
≤1.3 within 48 hours of FFP administration was associated with a significantly higher risk of 
death within 30 days of admission for ICH cases (adjusted Hazard Ratio=2.55; 95%CI: 1.04–
6.28), but not for non-ICH cases [7]. With a larger sample size, we have more precisely 
estimated the association between INR correction and mortality, and in particular for treated 
patients. This finding is particularly relevant for the increasing adoption of direct oral 
anticoagulant agents and their specific antidotes, suggesting that haemostatic assay corrections, 
which are relatively quick to assess compared with longer-term clinical outcomes, could be 
used in future trials to predict the efficacy of reversal agents.  
 
Strengths and limitations 
The study data were prospectively collected using patients’ clinical notes within a short 
timeframe of the major bleeding event and not retrospectively identified through administrative 
databases, thus minimising reporting and selection bias. The data had been submitted by 
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multiple hospitals across the UK, making our findings generalisable to major bleeding patients 
on VKAs for whom the mainline treatment consists of PCC and Vitamin K. The exact timing 
of onset of major bleeding prior to admission cannot be ascertained in most cases, but it seems 
a reasonable assumption that very few will be asymptomatic and delay presentation to hospital, 
and therefore hospital admission is an acceptable proxy. An upper limit of 2 days post-
admission was set for inclusion of interventions and INR results for analysis; this was to ensure 
that only factors in close proximity to onset of bleeding were analysed, such that the prognostic 
value of post-intervention INR on outcomes could be assessed without being confounded by 
subsequent complications. Without complete data on the exact time treatments were 
administered, post-treatment INR results inevitably do not always correspond to the same 
elapsed time after intervention for each patient. This was addressed first by ascertaining 
whether treatment preceded or followed INR result, and examining the influence that time 
elapsed in hours (where available) had on the results. Furthermore, whilst we believe the 
classification of bleeding sites into ICH and non-ICH is the primary and most clinically 
significant distinction, we accept that additional data on other measures of bleeding severity 
could have enhanced findings; as in other observational studies, treatment decisions for patients 
will be influenced by perceived clinical severity and even after trying to adjust for this, the 
possibility of residual confounding remains. Lastly, the amount of missing data in post-
intervention INR (31%) is a limitation. The use of multiple imputation which relied on clinical 
insight and exploratory analyses to inform auxiliary variable selection helped to make the 
missing at random assumption more plausible and, in turn, allowed data from all patients to be 
analysed and improved precision of estimates. For example, length of hospital stay was 
confirmed as an important predictor of INR being missing. The final results were in very close 
agreement to those from complete case analysis which give some assurance that the imputation 
model and missing data mechanism had been correctly specified.  
 
In conclusion, failure of INR correction is an important risk factor for mortality in major 
bleeding associated with VKAs, for both ICH and non-ICH patients. The findings support the 
hypothesis that correction of haemostatic assays could be used as surrogates for a variety of 
clinical outcomes in order to assess efficacy of reversal agents for oral anticoagulant agent 
bleeding. Higher doses of Vitamin K are more efficacious in correcting INR, but further studies 




Contribution to authorship:  
JT, LG, PM and JKM designed the study, wrote the manuscript and made all subsequent revisions. JT 
and JKM performed the analyses. NC, SS and CT contributed to the design of the study and writing of 
the manuscript.  
 
Funding 
The study was funded by the British Society for Hematology Early Stage Researcher Fellowship 
awarded to LG. The views expressed in this publication are those of the authors and not those of the 
funder. The funder had no role in the study design, data collection/analysis or preparation of this article.  
 
Acknowledgments  
We would like to acknowledge all hospitals, NHS trusts and principal investigators who reported to the 
study: Newham University Hospital (Dr Olivia Kreze), Whipps Cross University Hospital (Dr Peter 
MacCallum); The Royal London Hospital (Dr Laura Green); Barking Havering and Redbridge 
University Hospitals (Dr Khalid Saja); John Radcliffe Hospital (Dr Nicola Curry); Glasgow Royal 
Infirmary (Dr Campbell Tait); University Hospital of Wales (Dr Raza Alikhan); Sheffield Teaching 
Hospitals (Dr Rhona Maclean); Basingstoke & North Hampshire Hospital and Salisbury District 
Hospital (Dr Tamara Everington); Ulster Hospital (Dr Margaret Bowers); Wexham Park Hospital (Dr 
Sarah Wilson); Withybush General Hospital (Dr Sumant Kundu); Newcastle upon Tyne Hospitals (Dr 
John Hanley); North Middlesex University Hospital (Dr John Luckit); Basildon and Thurrock Hospitals 
(Dr Godwin Simon); Torbay Hospital (Dr Nichola Rymes); University College Hospital (Dr Hannah 
Cohen); St George's Healthcare NHS Trust (Dr James Uprichard); Birmingham Heartlands Hospital 
(Dr Charalampos Kartsios); Royal Bournemouth Hospital (Dr Jason Mainwaring); Hull and East 
Yorkshire Hospitals NHS Trust (Dr Salama Abosaad); Northern Lincolnshire and Goole NHS 
Foundation Trust (Dr Sanjeev Jalihal); Dumfries and Galloway Royal Infirmary (Dr Mohamed Khan); 
University Hospitals of North Midlands (Dr Deepak Chandra); Gloucestershire Hospitals (Dr Oliver 
Miles); South Tees Hospitals (Dr Jamie Maddox); Glangwili General Hospital (Dr Saran Nicholas); 
Royal Berkshire NHS Foundation Trust (Dr Liza Keating); University Hospital Southampton (Dr Sara 
Boyce); Northumbria Healthcare NHS  Foundation Trust (Dr Charlotte Bomken); and North Cumbria 





Conflict of interests:  
All authors declare the following: LG, JKM, JT, NC and SS have no conflicts of interest to disclose. 
CT has received consultancy and speaker honoraria, and travel support to attend scientific meetings 
from Bayer and Boehringer Ingelheim, and consultancy honoraria from BMS/Pfizer. PM has served as 
a speaker for Bayer and Daiichi-Sankyo, as a consultant for Daiichi-Sankyo, and has received travel 




1 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in 
patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 
2014; 124: 2450-8. blood-2014-07-590323 [pii];10.1182/blood-2014-07-590323 [doi]. 
2 Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M. Guidelines on 
oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011; 154: 311-24. 
10.1111/j.1365-2141.2011.08753.x [doi]. 
3 Sarode R, Milling TJ, Jr., Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy 
and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists 
presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 
2013; 128: 1234-43. 10.1161/CIRCULATIONAHA.113.002283. 
4 Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, Bendszus M, Bosel J, Christensen 
H, Dohmen C, Hennerici M, Kollmer J, Stetefeld H, Wartenberg KE, Weimar C, Hacke W, Veltkamp R. 
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial 
haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016; 15: 
566-73. 10.1016/S1474-4422(16)00110-1. 
5 Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart A, American College of Cardiology F. 
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. 
Circulation. 2003; 107: 1692-711. 10.1161/01.CIR.0000063575.17904.4E. 
6 Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate 
for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane 
Database Syst Rev. 2015: CD010555. 10.1002/14651858.CD010555.pub2. 
7 Menzin J, Hoesche J, Friedman M, Nichols C, Bergman GE, Crowther M, Garcia D, Jones C. 
Failure to correct International Normalized Ratio and mortality among patients with warfarin-related 
major bleeding: an analysis of electronic health records. J Thromb Haemost. 2012; 10: 596-605. 
10.1111/j.1538-7836.2012.04636.x. 
8 Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, 
Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in 
treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant 
therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and 
prothrombin complex concentrates. Stroke. 2006; 37: 1465-70. 
10.1161/01.STR.0000221786.81354.d6. 
9 Green L, Tan J, Morris JK, Alikhan R, Curry N, Everington T, Maclean R, Saja K, Stanworth S, 
Tait C, MacCallum P. A three-year prospective study of the presentation and clinical outcomes of 
major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). 
Haematologica. 2018; 103: 738-45. 10.3324/haematol.2017.182220. 
10 Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization 
Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical 
investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 
2005; 3: 692-4. 10.1111/j.1538-7836.2005.01204.x. 
11 Rubin DB. Multiple imputation for nonresponse in surveys. New York ;: Wiley, 1987. 
12 Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann 
M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during 
treatment with dabigatran or warfarin. Circulation. 2013; 128: 2325-32. 
CIRCULATIONAHA.113.002332 [pii];10.1161/CIRCULATIONAHA.113.002332 [doi]. 
13 Moustafa F, Stehouwer A, Kamphuisen P, Sahuquillo JC, Samperiz A, Alfonso M, Pace F, 
Surinach JM, Blanco-Molina A, Mismetti P, Monreal M, Investigators R. Management and outcome 
of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. Thromb 
Res. 2018; 171: 74-80. 10.1016/j.thromres.2018.09.049. 
14 
 
14 Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of 
bleeding in patients on antithrombotic agents. Br J Haematol. 2013; 160: 35-46. 10.1111/bjh.12107 
[doi]. 
15 Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS, Australasian Society of T, 
Haemostasis. An update of consensus guidelines for warfarin reversal. Med J Aust. 2013; 198: 198-9. 
10.5694/mja12.10614. 
16 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and 
management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 160S-98S. 10.1378/chest.08-0670. 
17 Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, 
Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, 
Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, 
Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider 
H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs AE, 
Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB. Anticoagulant 
reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-





Figure 1:  Sites of Bleeding (n = 1,771) 
 
Explanation of Other 
  
Visceral Haemoptysis; Pericardium; Retroperitoneal; Abdomen; 
Chest/Thoracic 
Genitourinary Haematuria/Urethral; Vaginal 
Musculo-mucosal-skeletal (MMS) Epistaxis or mucosal; Cutaneous or soft tissue; Intra-articular; 
Oral/Pharyngeal 
Miscellaneous Surgical site; Intraocular; Puncture site; Unknown; Other not 
covered above 
(cases with more than 1 of the above classified according to priority described in text.) 






















Figure 2:  INR results at T1 (pre-intervention) and T2 (post-intervention), intracranial 






INR: international normalised ratio; ICH: intracranial haemorrhage; IQR: interquartile range 




 ICH Non-ICH 
Time Period n INR, Median (IQR) n INR, Median (IQR) 
T1 714 2.7 (2.2 – 3.5) 877 3.9 (2.7 – 7.1) 
T2 509 1.2 (1.1 – 1.3) 713 1.3 (1.1 – 1.6) 
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Figure 3:  Predicted probability of T2 INR correction, by Intracranial Haemorrhage (ICH), 
Prothrombin Complex Concentrate (PCC) dose and Vitamin K dose, for a patient 





Table 1: Interventions (reversal agents and red cells and fresh frozen plasma administered) within 2 
days for Management of Major Bleeding on VKA 
 
Total ICH non-ICH  







       
Any intervention 1574 (85.9) 747 (92.5) 827 (85.9)        
PCC (any dose) 1364 (77.0) 704 (87.1) 660 (68.5) 
<1000 IU 37 (2.1) 17 (2.1) 20 (2.1) 
1000 – 1999 IU 330 (18.6) 166 (20.5) 164 (17.0) 
2000-2999 IU 624 (35.2) 349 (43.2) 275 (28.6) 
3000+ IU 362 (20.4) 164 (20.3) 198 (20.6) 
Unknown dose 11 (0.6) 8 (1.0) 3 (0.3) 
       
Vitamin K (any dose) 1296 (73.2) 620 (76.7) 676 (70.2) 
1-4 mg 116 (6.6) 23 (2.9) 93 (9.8) 
5 mg 495 (27.9) 244 (30.2) 251 (26.1) 
6-9 mg 15 (0.9) 4 (0.5) 11 (1.1) 
10 mg 576 (32.5) 298 (36.9) 278 (28.9) 
>10 mg 14 (0.8) 5 (0.6) 9 (0.9) 
Unknown dose 80 (4.5) 46 (5.7) 34 (3.4)        
Red Blood Cells 574 (32.4) 29 (3.6) 545 (56.6) 
Fresh Frozen Plasma 68 (3.8) 8 (1.0) 60 (6.2) 
       
FEIBA/FVIIa/FgC 3 (0.2) 0 (0.0) 3 (0.3)        
ICH: intracranial haemorrhage; PCC: prothrombin complex concentrate; FEIBA:  factor eight inhibitor 




Table 2:  Analysis of association between T2 INR correction and 30-day in-hospital mortality 
by univariable and multivariable logistic regression models 
 
Complete cases (n=1191) 
 
Multiple Imputation (n=1771) 
  OR 95%CI p-value   OR 95%CI p-value 
Univariable analysis          
T2 INR ≤ 1.3 1     1    
T2 INR > 1.3 1.54 1.12 2.12 0.008  1.57 1.18 2.09 0.002 
          
Multivariable analysis          
T2 INR >1.3 1.59 0.98 2.58 0.86 
 
1.54 0.99 2.42 0.06 
(in untreated group)          
          
T2 INR >1.3 3.18 1.93 5.23 <0.001  3.26 2.13 4.98 <0.001 
(in treated group)          
          
OR = odds ratio; CI = confidence interval; INR= international normalized ratio 
For multivariable analysis, odds ratios are adjusted for treatment (treated/untreated), intracranial haemorrhage 





Appendix 1 (Supplementary)  
 
Table 3:  Summary of multiple imputation variables and % missing (N=1771) 




Primary variables      
Death within 30 days of bleeding (Outcome) - - - 52 3 
T2 INR (Exposure) 1.2 1.1 1.4 549 31 
      
Auxiliary variables      
T1 INR 3.2 2.4 5.1 180 10 
T1 Prothrombin time, seconds 38.3 25.8 61.3 969 55 
T2 Prothrombin time, seconds 13.4 12 16 1043 59 
T1 Activated partial thromboplastin time, seconds 40 33 51 803 45 
T2 Activated partial thromboplastin time, seconds 29.2 25.6 34 977 55 
T1 Serum Creatinine, µmol/L 94 72 134 141 8 
T1 Alanine transaminase, IU/L  19 14 28 562 32 
T1 plasma haemoglobin, g/dL 11.6 8.9 13.4 81 5 
T1 platelet count, x109/L 222 171 288 91 5 
Length of hospital stay, days 7 3 17 12 <1 
Weight, kg 73 62 86 872 49 
Vitamin K dose, mg 5 0 10 80 4 
Vitamin K dose squared, mg2 25 0 100 80 4 
Prothrombin Complex Concentrate dose, IU 2000 500 2500 11 1 
Time between treatment and T2 INR, hours 9.5 5.0 18.8 816 46 
      
T1: pre-intervention (within 1 day of admission for major bleeding) 
T2: post-intervention (first result after intervention, or after T1 if no intervention given, and within 2 
days of admission for major bleeding) 
p25 – lower quartile; p75 – upper quartile 
INR=international normalised ratio 
 
 
Other auxiliary variables with no missing data 
Age, years 
Sex 
Intracranial haemorrhage (ICH) 
Did not receive any intervention before measurement of T2 INR 
Administration of Prothrombin Complex Concentrate, any dose 
Administration of Vitamin K, any dose 
Transfusion of Fresh Frozen Plasma, units 
Hospital proportion of patients with T1 INR recorded (proxy for quality of routine INR monitoring) 
Indicated warfarin/VKA for mechanical heart valve 
Haemorrhagic cerebrovascular accident during follow-up 
Admission to ITU during follow-up 
Any history of liver failure/cirrhosis, cancer or chronic renal failure 
 
